Skip to main
BMEA
BMEA logo

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 29%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion Inc. is advancing novel therapeutic options for diabetes and obesity, particularly through its lead candidate icovamenib, which has demonstrated significant benefits in glycemic control and weight management when combined with GLP-1-based therapies. Preclinical and clinical studies highlight icovamenib's potential to enhance the efficacy and tolerability of existing treatments, evidenced by meaningful reductions in HbA1c levels and improved glucose metabolism metrics compared to standalone therapies. The company’s proprietary FUSION System discovery platform underpins its strong pipeline, positioning Biomea Fusion favorably in a growing market for metabolic disease interventions.

Bears say

The analysis indicates a negative outlook on Biomea Fusion due to several significant risks impacting its valuation. Key concerns include the potential for failed or inconclusive clinical trials, which could hinder product development, and difficulties in securing adequate funding to support ongoing research and development initiatives. Additionally, the threat of dilutive capital raises further complicates the financial stability of the company, contributing to a conservative reassessment of its target valuation at $16.00.

BMEA has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 29% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Buy based on their latest research and market trends.

According to 14 analysts, BMEA has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.